论文部分内容阅读
目的:探讨红霉素与阿奇霉素治疗小儿支原体肺炎的临床疗效。方法:选取2013年5月到2014年10月于我院就诊的82例小儿支原体肺炎患者作为本次研究的对象,将患者平均分为甲组与乙组,每组各41例患者,甲组采用红霉素药物进行治疗,乙组采用阿奇霉素药物进行治疗,比较两组患者的临床治疗效果以及不良反应的发生率。结果:甲组患者的治疗总有效率为75.61%,乙组患者的治疗总有效率为95.12%,对比两组的临床治疗效果,乙组要明显优于甲组,具有显著差异(x2=6.248,P=0.012),有统计学意义;甲组不良反应发生率为24.39%,乙组不良反应发生率为7.32%,对比两组患者的不良反应发生率,乙组要明显低于甲组,差异存在显著性(X2=4.479,P=0.034),有统计学意义。结论:采用阿奇霉素治疗小儿支原体肺炎的临床治疗效果要明显优于红霉素治疗,且不良反应较少,值得在临床上大力推广与优先使用。
Objective: To investigate the clinical efficacy of erythromycin and azithromycin in the treatment of children with mycoplasma pneumonia. Methods: Totally 82 children with mycoplasma pneumonia who were treated in our hospital from May 2013 to October 2014 were enrolled in this study. Patients were divided equally into group A and group B, with 41 patients in each group. Group A The use of erythromycin drugs for treatment, the second group with azithromycin drugs for treatment, the two groups of patients compared the clinical effect and the incidence of adverse reactions. Results: The total effective rate of treatment in group A was 75.61%, and the total effective rate in group B was 95.12%. Compared with the clinical efficacy of group B, group B was significantly better than group A (x2 = 6.248 , P = 0.012), with statistical significance. The incidence of adverse reactions in group A was 24.39%, and the incidence of adverse reactions in group B was 7.32%. Compared with the incidence of adverse reactions in group B, group B was significantly lower than group A, The difference was significant (X2 = 4.479, P = 0.034), with statistical significance. Conclusion: The treatment of azithromycin in children with mycoplasma pneumonia is significantly better than the efficacy of erythromycin treatment, and fewer adverse reactions, it is worth to clinically promote and give priority to use.